Dr. Reddy's Laboratories Limited
DRREDDY · Pharma · NSE
₹1,269
Current Market Price
Fair Value (DCF)
₹1,519
Discount to FV
+19.7%
Updated 4h ago
YieldIQ Score
55/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
57%
ROE
11.4%
Debt/Equity
0.21
WACC
9.5%
Market Cap
₹1.06 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.4%
Return on capital employed
EV / EBITDA
14.0×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
15.7×
EBIT covers interest
Current Ratio
1.80×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,268.5
Bear case
Discount -42.0%
Base case
Discount +16.5%
Bull case
Discount +38.3%
Ratio Trends
DRREDDY · last 9 annual periods
ROE
11.4%
ROCE
17.4%
Operating Margin
—
Debt / Equity
0.21×
PE
24.4×
EV / EBITDA
14.0×
Historical Financials
DRREDDY · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹21.4K Cr | ₹24.6K Cr | ₹27.9K Cr | ₹32.6K Cr | ₹33.6K Cr | +11.9% |
| EBITDA | ₹4508 Cr | ₹7443 Cr | ₹8842 Cr | ₹9667 Cr | ₹7916 Cr | +15.1% |
| EBIT | ₹3087 Cr | ₹6154 Cr | ₹7357 Cr | — | — | +24.3% |
| PAT | ₹2357 Cr | ₹4507 Cr | ₹5568 Cr | ₹5654 Cr | ₹4285 Cr | +16.1% |
| EPS (diluted) | ₹131.21 | ₹270.90 | ₹334.59 | — | — | +26.4% |
| CFO | ₹2811 Cr | ₹5888 Cr | ₹4543 Cr | ₹4643 Cr | ₹5676 Cr | +19.2% |
| CapEx | ₹-1905 Cr | ₹-1887 Cr | ₹-2744 Cr | ₹-3440 Cr | ₹-3843 Cr | — |
| FCF | ₹906 Cr | ₹4001 Cr | ₹1800 Cr | ₹1203 Cr | ₹1833 Cr | +19.3% |
| Total Assets | ₹29.3K Cr | ₹32.2K Cr | ₹38.8K Cr | ₹49.3K Cr | ₹57.9K Cr | +18.6% |
| Total Debt | ₹3385 Cr | ₹1347 Cr | ₹2002 Cr | ₹4677 Cr | ₹7734 Cr | +23.0% |
| Shareholders' Equity | ₹19.1K Cr | ₹23.1K Cr | ₹28.1K Cr | ₹33.3K Cr | ₹37.7K Cr | +18.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
DRREDDY vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 ZYDUSLIFE ZYDUSLIFE | — | — | Pending | 17.2% | — |
 CIPLA CIPLA | — | — | Pending | 11.3% | 25.5× |
 LUPIN LUPIN | — | — | Pending | 23.8% | 19.8× |
 MANKIND MANKIND | — | — | Pending | 11.7% | — |
 AUROPHARMA AUROPHARMA | — | — | Pending | 9.2% | 21.4× |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹35.00/sh
Last payout
2025-07-10
₹8.00
Peak payout
₹8.00
Trailing yield
0.63%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Dr. Reddy's Laboratories Limited (DRREDDY.NS) trades at 1268.50 vs a model fair value of 1518.61, a gap of 19.7%. Piotroski F-score: 4/9....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of DRREDDY →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for DRREDDY →
Compare
Head-to-head with peers
Compare DRREDDY side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse DRREDDYNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.